 Scancell has signed a deal worth up to US208mln in upfront and milestone payments to license its anti-glycan antibody to cancer therapy specialist Genmab CSE:GEN. A US24bn Nasdaq-listed Danish group, Genmab has been granted an exclusive worldwide licence to develop and commercialise the antibody for all therapeutic and disease areas barring cell therapies. 